文献速递药物相互作用

Tusamitamab Ravtansine(DM4偶联物)给药后CYP酶下调的体外-体内外推预测

Prediction of CYP Down Regulation after Tusamitamab Ravtansine Administration (a DM4-Conjugate), Based on an In Vitro-In Vivo Extrapolation Approach.
PubMed 文献 · Clin Pharmacol Ther · 2023-12-03

本研究评估抗体偶联药物tusamitamab ravtansine的载荷DM4及其主要代谢物Me-DM4作为CYP酶介导药物相互作用肇事者的潜力。人肝细胞体外研究显示Me-DM4浓度依赖性下调CYP3A4、1A2和2B6,因DM4不稳定未能测定其体外常数。基于群体PK模型和生理药代动力学静态法建立的IVIVE-PK模型预测CYP3A4最大丰度短暂降低<10%,对应咪达唑仑AUC比值为1.14,认为体外CYP下调预期无临床相关性。

要点

  • Me-DM4在体外浓度依赖性下调CYP3A4、1A2和2B6,DM4因不稳定未获体外常数。
  • IVIVE-PK模型预测CYP3A4最大丰度短暂降低<10%,咪达唑仑AUC比值1.14。
  • 基于模型预测,Me-DM4的体外CYP下调预期无临床相关影响。

核心结论

  • 观察到的Me-DM4体外CYP下调预期无临床相关影响。

研究设计与样本

  • 人肝细胞体外研究评估Me-DM4对CYP3A4、1A2和2B6的下调,并建立基于IVIVE的药代动力学模型进行预测。
  • 采用群体PK模型预测DM4和Me-DM4循环浓度,并基于生理药代动力学静态法模拟对咪达唑仑暴露的影响。

主要发现

  • Me-DM4在人肝细胞中引起CYP3A4、1A2和2B6浓度依赖性下调。
  • DM4在研究孵育条件下不稳定,未能测定其体外常数。
  • IVIVE-PK模型显示CYP3A4丰度降低最大,从基线短暂降低<10%。
  • CYP3A4最大丰度降低对应预测咪达唑仑AUC比值为1.14。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tusamitamab ravtansine is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody (IgG1) and DM4 payload. Even if DM4 and its main metabolite methyl-DM4 (Me-DM4) circulate at low concentrations after ADC administration, their potential as perpetrators of cytochrome P450 mediated drug-drug interaction was assessed. In vitro studies in human hepatocytes indicated that Me-DM4 elicited a clear concentration-dependent down regulation of cytochrome P450 enzymes (CYP3A4, 1A2, and 2B6). Because DM4 was unstable under the incubation conditions studied, the in vitro constants could not be determined for this entity. Thus, to predict the clinical relevance of this observed downregulation, an in vitro-in vivo extrapolation (IVIVE) pharmacokinetic (PK) based approach was developed. To mitigate model prediction errors and because of their similar inhibitory effect on tubulin polymerization, the same downregulation constants were used for DM4 and Me-DM4. This approach describes the time course of decreasing CYP3A4, 1A2, and 2B6 enzyme amounts as a function of circulating concentrations of DM4 and Me-DM4 predicted from a population PK model. The developed IVIVE-PK model showed that the highest CYP abundance decrease was observed for CYP3A4, with a transient reduction of < 10% from baseline. The impact on midazolam exposure, as probe substrate of CYP3A, was then simulated based on a physiologically-based PK static method. The maximal CYP3A4 abundance reduction was associated with a predicted midazolam area under the curve (AUC) ratio of 1.14. To conclude, the observed in vitro downregulation of CYPs by Me-DM4 is not expected to have relevant clinical impact.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Pouzin C, Teutonico D, Fagniez N, et al. Prediction of CYP Down Regulation after Tusamitamab Ravtansine Administration (a DM4-Conjugate), Based on an In Vitro-In Vivo Extrapolation Approach. Clin Pharmacol Ther. 2023. PMID: 37964462. doi:10.1002/cpt.3102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。